[Paroxysmal tachycardia in infant and child; 7 personal observations].

M. Jeune,R. Carrón,A. Perrin

1955-06-22

Abstract:

What problem does this paper attempt to address?

Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment

Eva M. Boorsma,Jozine M. ter Maaten,Kevin Damman,Wilfried Dinh,Finn Gustafsson,Steven Goldsmith,Daniel Burkhoff,Faiez Zannad,James E. Udelson,Adriaan A. Voors

DOI: https://doi.org/10.1038/s41569-020-0379-7

IF: 49.421

2020-05-15

Nature Reviews Cardiology

Abstract:Congestion is the main reason for hospitalization in patients with acute decompensated heart failure and is an important target for therapy. However, achieving complete decongestion can be challenging. Furthermore, residual congestion before discharge from hospital is associated with a high risk of early rehospitalization and death. An improved understanding of the pathophysiology of congestion is of great importance in finding better and more personalized therapies. In this Review, we describe the two different forms of congestion — intravascular congestion and tissue congestion — and hypothesize that differentiating between and specifically treating these two different forms of congestion could improve the outcomes of patients with acute decompensated heart failure. Although the majority of these patients have a combination of both intravascular and tissue congestion, one phenotype can dominate. Each of these two forms of congestion has a different pathophysiology and requires a different diagnostic approach. We provide an overview of novel and established biomarkers, imaging modalities and mechanical techniques for identifying each type of congestion. Treatment with loop diuretics, the current cornerstone of decongestive treatment, reduces circulating blood volume and thereby reduces intravascular congestion. However, the osmolality of the circulating blood decreases with the use of loop diuretics, which might result in less immediate translocation of fluid from the tissues (lungs, abdomen and periphery) to the circulation when the plasma refill rate is exceeded. By contrast, aquaretic drugs (such as vasopressin antagonists) predominantly cause water excretion, which increases the osmolality of the circulating blood, potentially improving translocation of fluid from the tissues to the circulation and thereby relieving tissue congestion.

cardiac & cardiovascular systems
The Congestion "Pandemic" in Acute Heart Failure Patients

Daniela Mocan,Radu Ioan Lala,Maria Puschita,Luminita Pilat,Dan Alexandru Darabantiu,Adina Pop-Moldovan

DOI: https://doi.org/10.3390/biomedicines12050951

IF: 4.757

2024-04-25

Biomedicines

Abstract:Congestion not only represents a cardinal sign of heart failure (HF) but is also now recognized as the primary cause of hospital admissions, rehospitalization, and mortality among patients with acute heart failure (AHF). Congestion can manifest through various HF phenotypes in acute settings: volume overload, volume redistribution, or both. Recognizing the congestion phenotype is paramount, as it implies different therapeutic strategies for decongestion. Among patients with AHF, achieving complete decongestion is challenging, as more than half still experience residual congestion at discharge. Residual congestion is one of the strongest predictors of future cardiovascular events and poor outcomes. Through this review, we try to provide a better understanding of the congestion phenomenon among patients with AHF by highlighting insights into the pathophysiological mechanisms behind congestion and new diagnostic and management tools to achieve and maintain efficient decongestion.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Assessment of filling pressures and fluid overload in heart failure: an updated perspective

Rafael de la Espriella,Marta Cobo,Enrique Santas,Frederik H Verbrugge,Marat Fudim,Nicolas Girerd,Gema Miñana,José Luis Górriz,Antoni Bayés-Genís,Julio Núñez

DOI: https://doi.org/10.1016/j.rec.2022.07.009

Abstract:Congestion plays a major role in the pathogenesis, presentation, and prognosis of heart failure and is an important therapeutic target. However, its severity and organ and compartment distribution vary widely among patients, illustrating the complexity of this phenomenon. Although clinical symptoms and signs are useful to assess congestion and manage volume status in individual patients, they have limited sensitivity and do not allow identification of congestion phenotype. This leads to diagnostic uncertainty and hampers therapeutic decision-making. The present article provides an updated overview of circulating biomarkers, imaging modalities (ie, cardiac and extracardiac ultrasound), and invasive techniques that might help clinicians to identify different congestion profiles and guide the management strategy in this diverse population of high-risk patients with heart failure.
Phthalocyanine metal complexes in catalysis.

A. Sorokin

DOI: https://doi.org/10.1021/cr4000072

IF: 62.1

2013-06-19

Chemical Reviews

Abstract:
Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview

Rafael de la Espriella,Enrique Santas,Isabel Zegri Reiriz,Jose Luis Górriz,Marta Cobo Marcos,Julio Núñez

DOI: https://doi.org/10.1016/j.nefroe.2021.04.007

Abstract:Renal sodium and water retention with resulting extracellular volume expansion and redistribution are hallmark features of heart failure syndromes. However, congestion assessment, monitoring, and treatment represent a real challenge in daily clinical practice. This document reviewed historical and contemporary evidence of available methods for determining volume status and discuss pharmacological aspects and pathophysiological principles that underlie diuretic use.
Decongestion in acute heart failure: Is it time to change diuretic‐centred paradigm?

Jan Biegus,Gad Cotter,Marco Metra,Piotr Ponikowski

DOI: https://doi.org/10.1002/ejhf.3423

2024-08-23

European Journal of Heart Failure

Abstract:Guideline directed medical therapy (GDMT)‐centred decongestion in heart failure (HF). ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor–neprilysin inhibitor; CVP, central venous pressure; MRA, mineralocorticoid receptor antagonist; PCWP, pulmonary capillary wedge pressure; RAAS, renin–angiotensin–aldosterone system; SGLT‐2i, sodium–glucose cotransporter 2 inhibitor; SNS, sympathetic nervous system. Congestion is a common cause of clinical deterioration and the most common clinical presentation at admission in acute heart failure (HF). Therefore, finding effective and sustainable ways to alleviate congestion has become a crucial goal for treating HF patients. Congestion is a result of complex underlying pathophysiology; therefore, it is not a direct cause of the disease but its consequence. Any therapy that directly promotes sodium/water removal only, thus targeting only clinical symptoms, neither modifies the natural course of the disease nor improves prognosis. This review aims to provide a comprehensive evaluation of the current decongestive therapies and propose a new (not diuretic‐centred) paradigm of long‐term congestion management in HF that attempts to correct the underlying pathophysiology, thus improving congestion, preventing its development, and favourably altering the natural course of the disease rather than merely treating its symptoms.

cardiac & cardiovascular systems
Biomarkers of Hemodynamic Congestion in Heart Failure

Alison Brann,Sean Selko,Ethan Krauspe,Kevin Shah

DOI: https://doi.org/10.1007/s11897-024-00684-8

Abstract:Purpose of review: The purpose of this review is to describe the evidence behind various blood and imaging-based biomarkers that can improve the identification of congestion when not clearly evident on routine examination. Recent findings: The natriuretic peptides (NPs) BNP and NT-proBNP have been shown to closely correlate with intra-cardiac filling pressures, both at baseline and when trended following improvement in congestion. Additionally, NPs rise well before clinical congestion is apparent so can be used as a tool to help identify subclinical HF decompensation. Additional serum-based biomarkers including MR-proANP and CA-125 can be helpful in assisting with diagnostic certainty when BNP or NT-proBNP are in the "grey zone" or when factors are present which may confound NP levels. Additionally, the emerging use of ultrasound techniques may enhance our ability to fine-tune the assessment and treatment of congestion. Biomarkers, including the blood-based natriuretic peptides and markers on bedside point of care ultrasound, can be used as non-invasive indices of hemodynamic congestion. These biomarkers are particularly valuable to incorporate when the degree of a patient's congestion is not apparent on clinical exam, and they can provide important prognostic information and help guide clinical management.
Contemporary Decongestive Strategies in Acute Heart Failure

Amir Kazory

DOI: https://doi.org/10.1016/j.semnephrol.2024.151512

IF: 4.472

2024-05-05

Seminars in Nephrology

Abstract:Summary Congestion is the primary driver of hospital admissions in patients with heart failure and the key determinant of their outcome. Although intravenous loop diuretics remain the predominant agents used in the setting of acute heart failure, the therapeutic response is known to be variable, with a significant subset of patients discharged from the hospital with residual hypervolemia. In this context, urinary sodium excretion has gained attention both as a marker of response to loop diuretics and as a marker of prognosis that may be a useful clinical tool to guide therapy. Several decongestive strategies have been explored to improve diuretic responsiveness and removal of excess fluid. Sequential nephron blockade through combination diuretic therapy is one of the most used methods to enhance natriuresis and counter diuretic resistance. In this article, I provide an overview of the contemporary decongestive approaches and discuss the clinical data on the use of add-on diuretic therapy. I also discuss mechanical removal of excess fluid through extracorporeal ultrafiltration with a brief review of the results of landmark studies. Finally, I provide a short overview of the strategies that are currently under investigation and may prove helpful in this setting.

urology & nephrology
HEMATOPORPHYRIN PHOTOSENSITIZATION OF SERUM ALBUMIN and SUBTILISIN BPN'

P. Richard,A. Blum,L. Grossweiner

DOI: https://doi.org/10.1111/j.1751-1097.1983.tb04474.x

1983-03-01

Photochemistry and Photobiology

Abstract:—The photosensitized inactivation of subtilisin BPN' by free hematoporphyrin (HP) followed exponential kinetics with positive mechanistic tests for the involvement of singlet oxygen (1O2) as the principal intermediate. The photoinactivation quantum yield was 0.029 at 390 nm in oxygen‐saturated, D2O buffer at pH 7.0. The effects of HP binding were investigated for tryptophan oxidation in bovine serum albumin (BSA) and human serum albumin (HSA) at high protein:HP concentration ratios where the HP was > 97% complexed. The reaction kinetics were non‐exponential and mimick a second‐order process in the initial stages. The rate of HP photobleaching was 30‐fold faster for complexed HP compared with free HP, which was shown to account for the observed kinetics. Mechanistic tests showed that 1O2 was the dominant photooxidizing intermediate of tryptophan residues and that it was not involved in the accompanying photobleaching of HP. The quantum yield for tryptophan oxidation in BSA was 0.11 at 390 nm in oxygen‐saturated, D2O buffer at pH 8.0. The reactivity of HSA was approximately 2‐fold lower than BSA for equivalent conditions. Estimates of the reaction cross sections led to 3 Å2 for the inactivation of subtilisin BPN' by 1O2 and 20 Å2 for the oxidation of tryptophan in BSA.
Different Patterns of Human Porphyria*

J. Waldenström,B. Haeger‐Aronsen

DOI: https://doi.org/10.1136/bmj.2.5352.272

1963-08-03

British Medical Journal

Abstract:guinea-pigs, or to act in a more limited capacity-for example, as an exclusion test. 6. It can be assumed that the compatibility or incompatibility revealed by the N.L.T. test applies to organs other than skin. 7. The N.L.T. test is to be thought of as an ad hoc measure which may be useful until the adoption of methods analogous to those used in erythrocyte grouping provide a definitive solution of the typing problem.
Exercise intervention in hospitalized heart failure patients, with emphasis on congestion-related complications: a review

Jirka Cops,Sibren Haesen,Bart De Moor,Wilfried Mullens,Dominique Hansen

DOI: https://doi.org/10.1007/s10741-019-09833-x

2019-07-25

Heart Failure Reviews

Abstract:The importance of physical activity has become evident since a sedentary lifestyle drives cardiovascular disease progression and is associated with increased morbidity and mortality. The favorable effects of exercise training in chronic heart failure (HF) and chronic kidney disease (CKD) are widely recognized and exercise training is recommended by European and American guidelines. However, the application of exercise intervention in HF patients hospitalized for acute decompensation or acute worsening in cardiac function has not been explored extensively and, as a result, knowledge about the effects of exercise training in the inpatient setting of acute HF is limited. Acute HF is often accompanied by signs and symptoms of congestion, termed acute decompensated heart failure (ADHF), which leads to worsening renal function (WRF) and eventually negatively affects both thoracic and abdominal organs. Therefore, we first provide a comprehensive overview of the impact of exercise training in hospitalized patients demonstrating acute decompensating HF. In the second part, we will focus on the effects of exercise training on congestion in a setting of ADHF complicated by renal dysfunction. This review suggests that exercise intervention is beneficial in the inpatient setting of acute HF, but that more clinical studies focusing on the application of exercise training to counteract venous congestion are needed.

cardiac & cardiovascular systems
How to diagnose and treat venous congestion in heart failure

Pierpaolo Pellicori,David Hunter,Htet Htet Ei Khin,John G F Cleland

DOI: https://doi.org/10.1093/eurheartj/ehad883

IF: 39.3

2024-01-14

European Heart Journal

Abstract:Heart failure (HF) is a clinical syndrome characterized by renal retention of salt and water due to cardiac dysfunction. 1 About 70% of the blood volume is contained in the systemic venous circulation. Due to their thin walls and high compliance, veins may dilate and accommodate large increases in blood volume with little or no increase in intravascular pressure. However, eventually, once the buffering capacity of the systemic venous system is exhausted, venous pressure will rise, leading to an increase in atrial and left ventricular filling pressures and wall stress and enhanced secretion of natriuretic peptides that should promote salt and water excretion, thereby limiting or reversing congestion. When the natriuretic peptide system is overwhelmed, congestion worsens, and the syndrome of HF develops. The rise in systemic venous pressure leads to increased transudation of water into the tissues, and when that exceeds lymphatic clearance capacity, organs and tissues will become oedematous, and symptoms and signs will develop. An increase in pulmonary venous pressure will lead to similar problems for the lung.

cardiac & cardiovascular systems
Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure

Jason Stencel,Indranee Rajapreyar,Rohan Samson,Thierry Le Jemtel

DOI: https://doi.org/10.1007/s11897-022-00573-y

Abstract:Purpose of the review: Progressive intravascular, interstitial, and alveolar fluid overload underlies the transition from compensated to acutely decompensated heart failure and loop diuretics are the mainstay of treatment. Adverse effects and resistance to loop diuretics received much attention while the contribution of a depressed cardiac output to diuretic resistance was downplayed. Recent findings: Analysis of experience with positive inotropic agents, especially dobutamine, indicates that enhancement of cardiac output is not consistently associated with increased renal blood flow. However, urinary output and renal sodium excretion increase likely due to dobutamine-mediated decrease in renal and systemic reduced activation of sympathetic nervous- and renin-angiotensin-aldosterone system. Mechanical circulatory support with left ventricular assist devices ascertained the contribution of low cardiac output to diuretic resistance and the pathogenesis and progression of kidney disease in acutely decompensated heart failure. Diuretic resistance commonly occurs in acutely decompensated heart failure. However, failure to resolve fluid overload despite high doses of loop diuretics should alert to the presence of a low cardiac output state.
The Conotruncus: I. Its Normal Inversion and Conus Absorption

M. Lev

DOI: https://doi.org/10.1161/01.CIR.46.3.634

IF: 37.8

1972-09-01

Circulation

Abstract:measurements to the nearest millisecond may well imply unjustified precision when using a recording paper speed of 100 mm/sec and time lines of 10 msec, but it is unlikely that the precision of our data would be enhanced by measuring to the nearest 5 msec on paper with 20 msec time lines, as recommended by Weissler and co-workers,1 or to the nearest 5 msec on paper with 40 msec time lines, as reported by Aronow et al.2 The STIs obtained immediately following exercise were corrected for heart rate using regression equations developed in resting supine subjects.1 3 Such an approach has been used by other workers in this field,4 and it is our opinion that such corrections would at least partially neutralize the chronotropic effects of exercise and better expose other exercise-related hemodynamic alterations. Although we concur with Dr. Weissler that it would have been preferable to apply regression equations developed in supine exercising subjects, to our knowledge such data are not presently available. Furthermore, the ratio of PEP/LVET did not require heart rate correction. From the conceptual standpoint, we agree that the STIs deviate from normal in parallel with other hemodynamic parameters as quantitated by correlation coefficients. In our study, these noninvasive measurements permitted the separation of a group of patients with chronic coronary artery disease (CAD) from an ageand sexmatched group of normal subjects, the former group having a significantly longer PEPC, shorter LVETC, and larger PEP/LVET at rest and exercise. The abnormal STIs occurred predominantly in a subgroup of patients in the CAD group in whom significant abnormalities of strokevolume index, cardiac index, LV dP/dt, or ejection fraction existed. However, we must take issue with Dr. Weissler if he contends that the STIs reliably detect minor abnormalities of ventricular function in the individual patient with chronic CAD. Despite significant correlations in our report between the STIs and several directly measured hemodynamic parameters, the overlap in the data prevents any confident prediction of left ventricular dysfunction as conventionally defined unless the functional abnormalities are severe. For example, in our figure 2 which correlates the left ventricular ejection fraction as measured angiographically with PEP/LVET obtained immediately after exercise, a PEP/LVET of 0.30 was associated with ejection fractions varying from 0.40 to 0.90. This occurred despite the significant correlation (r -0.67; P < 0.0005) between these two variables. On the basis of our study, we are in agreement with Dr. Weissler that one should not attempt to predict from measurements of STIs such hemodynamic variables as cardiac index, stroke-volume index, left ventricular end-diastolic pressure, pulmonary artery and wedge pressures, exercise factor, or LV dP/dt, or attempt to predict the presence and extent of coronary artery disease or left ventricular asynergy as demonstrated on cineangiography. Furthermore, the available data suggest that the STIs cannot reliably separate the individual subject with normal cardiac function or normal coronary arteries from the patient with chronic CAD with mild-to-moderate left ventricular dysfunction. Yet it is in this latter group of patients rather than those with clinically more apparent abnormalities of ventricular performance that STIs might have offered the most useful contribution as a noninvasive bedside technic. If such indirectly obtained time intervals provide an imprecise potentially misleading measure of the underlying interdependent parameters of left ventricular function, then caution should be exercised in applying them in the clinical evaluation and follow-up of the individual patient with CAD.
Role of splanchnic circulation in the pathogenesis of heart failure: State-of-the-art review

Hidenori Yaku,Marat Fudim,Sanjiv J Shah,Sanjiv J. Shah

DOI: https://doi.org/10.1016/j.jjcc.2024.02.004

IF: 2.974

2024-02-01

Journal of Cardiology

Abstract:A hallmark of heart failure (HF), whether it presents itself during rest or periods of physical exertion, is the excessive elevation of intracardiac filling pressures at rest or with exercise. Many mechanisms contribute to the elevated intracardiac filling pressures, and notably, the concept of volume redistribution has gained attention as a cause of the elevated intracardiac filling pressures in patients with HF, particularly HF with preserved ejection fraction, who often present without symptoms at rest, with shortness of breath and fatigue appearing only during exertion. This phenomenon suggests cardiopulmonary system non-compliance and inappropriate volume distribution between the stressed and unstressed blood volume components. A substantial proportion of the intravascular blood volume is in the splanchnic vascular compartment in the abdomen. Preclinical and clinical investigations support the critical role of the sympathetic nervous system in modulating the capacitance and compliance of the splanchnic vascular bed via modulation of the greater splanchnic nerve (GSN). The GSN activation by stressors such as exercise causes excessive splanchnic vasoconstriction, which may contribute to the decompensation of chronic HF via volume redistribution from the splanchnic vascular bed to the central compartment. Accordingly, for example, GSN ablation for volume management has been proposed as a potential therapeutic intervention to increase unstressed blood volume. Here we provide a comprehensive review of the role of splanchnic circulation in the pathogenesis of HF and potential novel treatment options for redistributing blood volume to improve symptoms and prognosis in patients with HF.

cardiac & cardiovascular systems
Poor in-hospital congestion improvement in acute heart failure patients classified according to left ventricular ejection fraction: prognostic implications

Gaetano Ruocco,Nicolas Girerd,Tripti Rastogi,Zohra Lamiral,Alberto Palazzuoli

DOI: https://doi.org/10.1093/ehjci/jeae075

2024-03-13

European Heart Journal - Cardiovascular Imaging

Abstract:Abstract Aims Residual congestion in acute heart failure (AHF) is associated with poor prognosis. However, there is a lack of data on the prognostic value of changes in a combined assessment of in-hospital congestion. The present study sought to assess the association between in-hospital congestion changes and subsequent prognosis according to left ventricular ejection fraction (LVEF) classification. Methods and results Patients (N = 244, 80.3 ± 7.6 years, 50.8% male) admitted for acute HF in two European tertiary care centres underwent clinical assessment (congestion score included dyspnoea at rest, rales, third heart sound, jugular venous distention, peripheral oedema, and hepatomegaly; simplified congestion score included rales and peripheral oedema), echocardiography, lung ultrasound, and natriuretic peptides (NP) measurement at admission and discharge. The primary outcome was a composite of all-cause mortality and/or HF re-hospitalization. In the 244 considered patients (95 HF with reduced EF, 57 HF with mildly reduced EF, and 92 HF with preserved EF), patients with limited improvement in clinical congestion score (hazard ratio 2.33, 95% CI 1.51–3.61, P = 0.0001), NP levels (2.29, 95% CI 1.55–3.38, P < 0.0001), and the number of B-lines (6.44, 95% CI 4.19–9.89, P < 0.001) had a significantly higher risk of outcome compared with patients experiencing more sizeable decongestion. The same pattern of association was observed when adjusting for confounding factors. A limited improvement in clinical congestion score and in the number of B-lines was related to poor prognosis for all LVEF categories. Conclusion In AHF, the degree of congestion reduction assessed over the in-hospital stay period can stratify the subsequent event risk. Limited reduction in both clinical congestion and B-lines number are related to poor prognosis, irrespective of HF subtype.

radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems
A Multimodal Approach to Congestion Assessment

Silvia Crespo-Aznarez,Amelia Campos-Saenz de Santamaría,Marta Sánchez-Marteles,Claudia Josa-Laorden,Fernando Ruiz-Laiglesia,Beatriz Amores-Arriaga,Vanesa Garcés-Horna,Ruben Tejel-Puisac,María Angel Julián-Ansón,Ignacio Giménez-López,Juan Ignacio Pérez-Calvo,Jorge Rubio-Gracia

DOI: https://doi.org/10.3390/jcm13041053

IF: 3.9

2024-02-13

Journal of Clinical Medicine

Abstract:Background: Congestion is an essential issue in patients with heart failure (HF). Standard treatments do not usually achieve decongestion, and various strategies have been proposed to guide treatment, such as determination of natriuresis. After starting treatment with loop diuretics, we postulate that initial natriuresis might help treatment titration, decongestion, and improve prognosis. Methods: It was a prospective and observational study. Patients admitted with the diagnosis of HF decompensation were eligible. An assessment of congestion was performed during the first 48 h. Results: A total of 113 patients were included. A poor diuretic response was observed in 39.8%. After the first 48 h, patients with a greater diuretic response on admission (NaU > 80 mmol/L) showed fewer pulmonary b lines (12 vs. 15; p = 0.084), a lower IVC diameter (18 mm vs. 22 mm; p = 0.009), and lower IAP figures (11 mmHg vs. 13 mmHg; p = 0.041). Survival analysis tests demonstrated significant differences showing a higher proportion of all-cause mortality (ACM) and HF rehospitalization in the poor-diuretic-response group (log-rank test = 0.020). Conclusions: Up to 40% of the patients presented a poorer diuretic response at baseline, translating into worse outcomes. Patients with an optimal diuretic response showed significantly higher abdominal decongestion at 48 h and a better prognosis regarding ACM and/or HF rehospitalizations.

medicine, general & internal
Decongestion in Acute Heart Failure—Time to Rethink and Standardize Current Clinical Practice?

Valentin Bilgeri,Philipp Spitaler,Christian Puelacher,Moritz Messner,Agne Adukauskaite,Fabian Barbieri,Axel Bauer,Thomas Senoner,Wolfgang Dichtl

DOI: https://doi.org/10.3390/jcm13020311

IF: 3.9

2024-01-05

Journal of Clinical Medicine

Abstract:Most episodes of acute heart failure (AHF) are characterized by increasing signs and symptoms of congestion, manifested by edema, pleura effusion and/or ascites. Immediately and repeatedly administered intravenous (IV) loop diuretics currently represent the mainstay of initial therapy aiming to achieve adequate diuresis/natriuresis and euvolemia. Despite these efforts, a significant proportion of patients have residual congestion at discharge, which is associated with a poor prognosis. Therefore, a standardized approach is needed. The door to diuretic time should not exceed 60 min. As a general rule, the starting IV dose is 20–40 mg furosemide equivalents in loop diuretic naïve patients or double the preexisting oral home dose to be administered via IV. Monitoring responses within the following first hours are key issues. (1) After 2 h, spot urinary sodium should be ≥50–70 mmol/L. (2) After 6 h, the urine output should be ≥100–150 mL/hour. If these target measures are not reached, the guidelines currently recommend a doubling of the original dose to a maximum of 400–600 mg furosemide per day and in patients with severely impaired kidney function up to 1000 mg per day. Continuous infusion of loop diuretics offers no benefit over intermittent boluses (DOSE trial). Emerging evidence by recent randomized trials (ADVOR, CLOROTIC) supports the concept of an early combination diuretic therapy, by adding either acetazolamide (500 mg IV once daily) or hydrochlorothiazide. Acetazolamide is particularly useful in the presence of a baseline bicarbonate level of ≥27 mmol/L and remains effective in the presence of preexisting/worsening renal dysfunction but should be used only in the first three days to prevent severe metabolic disturbances. Patients should not leave the hospital when they are still congested and/or before optimized long-term guideline-directed medical therapy has been initiated. Special attention should be paid to AHF patients during the vulnerable post-discharge period, with an early follow-up visit focusing on up-titrate treatments of recommended doses within 2 weeks (STRONG-HF).

medicine, general & internal
The changing US health care agenda.

E. Ginzberg

DOI: https://doi.org/10.1001/JAMA.279.7.501

1998-02-18

Abstract:
LONG‐ACTING SULFONAMIDE (SULFAMETHOXYDIAZINE) IN THE THERAPY OF CHRONIC URINARY INFECTIONS

H. Seneca,H. Zinsser

DOI: https://doi.org/10.1111/j.1532-5415.1966.tb05600.x

1966-04-01

Journal of the American Geriatrics Society

Abstract:Sulfamethoxydiazine has been used in clinical medicine in Europe since 1961. Seneca (I.) in 1964 reviewed these reports, and included an additional 197 cases of urinary-tract infections treated with this drug. A total of 143 pathogens from 121 patients were included in this investigation. The side effects were less than 2 per cent: one patient had a skin rash with eosinophilia, 2 had a minor gastrointestinal upset, and a fourth had urinary discomfort. Twenty-four patients were completely cured. Forty-eight of 143 pathogens were .killed. Lewis in 1964 (2) reported the treatment of 148 cases of urologic infections with this drug. He concluded that it was an effective antibacterial agent in the management of acute and chronic pyelonephritis and cystitis, with a very low incidence of side effects. Noojin et al. in 1965 (3) reported the results of sulfamethoxydiazine therapy in 43 cases of pustular acne vulgaris: there was definite improvement in 37 (86 per cent). Side effects occurred in 4 patients: 2 had nasal stuffiness, 1 had edema of the lips and mouth, and 1 had mild transient leukopenia. Sulfamethoxydiazine is a long-acting systemic sulfonamide with a low-dosage advantage based on rapid and uniform absorption from the intestinal tract, maintenance of uirinary, tissue and serum levels, a low protein-binding rate, low acetylation, good tolerance and low toxicity. In studies conducted by Media et al. and reported in 1964 (4), the average serum half-life after a single dose was 36.6 hours, with a range of 29 to 58 hours. One gram by mouth gave a blood level of 8 mg per 100 ml in 4 hours, with 10 per cent acetylation and 90 per cent free sulfonamide. Thirty-four per cent was excreted in the urine in 24 hours, of which 67.2 per cent was free sulfonamide. The solubility of the free and conjugated forms is similar to that of sulfadimethoxine [Seneca, 1964 (5)]. The bile level after 1.5 grams orally was 2.2 to 22 mg per 100 ml in 4 hours, with detectable amounts a t the end of 24 hours, and 80 to 90 per cent as free sulfonamide. The spinal fluid level in 12 hours ranged from 1.2 to 1.6 mg per 100 ml free, and from 1.4 to 1.8 mg total sulfonamide; in 24 hours it ranged from 0.6 to 0.9 mg free, and from 0.9 to 1.1 mg total; and in 48 hours from 0.8 to 1.8 mg free, and from 1.0 to 1.9 mg total. The peritoneal fluid level after a 1.5-gram oral dose ranged from 0.4 to 0.9 mg per 100 ml free sulfonamide, with total sulfonamide ranging from 2.4 to 5.2 mg.

[Paroxysmal tachycardia in infant and child; 7 personal observations].

Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment

The Congestion "Pandemic" in Acute Heart Failure Patients

Assessment of filling pressures and fluid overload in heart failure: an updated perspective

Phthalocyanine metal complexes in catalysis.

Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview

Decongestion in acute heart failure: Is it time to change diuretic‐centred paradigm?

Biomarkers of Hemodynamic Congestion in Heart Failure

Contemporary Decongestive Strategies in Acute Heart Failure

HEMATOPORPHYRIN PHOTOSENSITIZATION OF SERUM ALBUMIN and SUBTILISIN BPN'

Different Patterns of Human Porphyria*

Exercise intervention in hospitalized heart failure patients, with emphasis on congestion-related complications: a review

How to diagnose and treat venous congestion in heart failure

Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure

The Conotruncus: I. Its Normal Inversion and Conus Absorption

Role of splanchnic circulation in the pathogenesis of heart failure: State-of-the-art review

Poor in-hospital congestion improvement in acute heart failure patients classified according to left ventricular ejection fraction: prognostic implications

A Multimodal Approach to Congestion Assessment

Decongestion in Acute Heart Failure—Time to Rethink and Standardize Current Clinical Practice?

The changing US health care agenda.

LONG‐ACTING SULFONAMIDE (SULFAMETHOXYDIAZINE) IN THE THERAPY OF CHRONIC URINARY INFECTIONS